Press Releases

Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry and generative AI capabilities in order to further create new chemical composition of matter for novel biological targets Advanced 4 active clinical trials, including an exploratory Phase 2 study of REC-994 in

SALT LAKE CITY and TORONTO and MONTRÉAL , May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space:

Salt Lake City , May 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Bank of America Securities 2023 Health Care

Salt Lake City , April 03, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: 22nd Annual Needham Virtual Healthcare

Highlights include the company’s significant progress in 2022 to create a more sustainable R&D model and advance potential new medicines to patients Salt Lake City , March 28, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology

SALT LAKE CITY , March 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Morgan Stanley Technology, Media & Telecom

Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readouts Delivered against core elements of our Roche-Genentech collaboration (neuroscience and an indication in gastrointestinal oncology) and Bayer collaboration

Salt Lake City, Utah , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rare Disease advocacy organizations and biotech and healthcare industry leaders will partner to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease. On Rare Disease Day, Feb.

SALT LAKE CITY , Feb. 1, 2023 /PRNewswire/ --  Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:     SVB Securities Global Biopharma Conference — February 14

For the first time ever, a demonstration version of one of Recursion's Compound Intelligence tools to explore maps of biology and chemistry is open for anyone to use RxRx3, the underlying dataset released alongside MolRec™, spans almost the entire human genome and is 76 times larger than all